Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet

BACKGROUND AND OBJECTIVE: Venetoclax is an approved BCL-2 inhibitor, currently under evaluation in different hematological malignancies in adult and pediatric populations. Venetoclax is available as 10, 50, and 100 mg tablets. To provide an alternative to patients who find taking the commonly prescr...

Descripción completa

Detalles Bibliográficos
Autores principales: Badawi, Mohamed, Chen, Xin, Marroum, Patrick, Suleiman, Ahmed A., Mensing, Sven, Koenigsdorfer, Anette, Schiele, Julia Teresa, Palenski, Tammy, Samineni, Divya, Hoffman, David, Menon, Rajeev, Salem, Ahmed Hamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338003/
https://www.ncbi.nlm.nih.gov/pubmed/35829925
http://dx.doi.org/10.1007/s40261-022-01172-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338003/
https://www.ncbi.nlm.nih.gov/pubmed/35829925
http://dx.doi.org/10.1007/s40261-022-01172-4

Ejemplares similares